ImmunityBio, Inc.

ImmunityBio, Inc. is a biotechnology company that creates and commercializes immunotherapies aimed at activating both the innate and adaptive immune systems to treat cancers and infectious diseases. Its core technology, the Cancer BioShield platform, integrates cytokine fusion proteins, adenovirus-vectored vaccine delivery systems, and natural killer (NK) cell therapies to stimulate critical lymphocytes and generate lasting immune memory. The company's lead commercial product is ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist antibody-cytokine fusion protein. Customers include adult patients suffering from non-muscle invasive bladder cancer unresponsive to standard therapy, as well as those with progressing metastatic non-small cell lung cancer receiving combination checkpoint inhibitor treatments.

The company's commercial operations span globally, with its lead product approved or conditionally authorized across 33 countries, including the United States, the United Kingdom, Saudi Arabia, and member states of the European Union. While commercial distribution and partnerships reach across North America, Europe, and the Middle East, the provided text does not identify specific corporate headquarters or facility counts.

Summary of the business section of ImmunityBio's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, ImmunityBio employed 691 employees, of which 41% are focused on research and development, 25% on manufacturing and quality, and 34% on selling, general and administrative functions.”